Kit Available Now for Distribution
LONDON, Jan. 4, 2023
/PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (Nasdaq:
VRAX), an innovative biotechnology company focused on the
prevention, detection, and diagnosis of viral diseases, announced
today the distribution of HPV test kits with shipments anticipated
in Q1 of 2023 to markets accepting the CE mark, such as the
European Union. The test kit covers 18 different genotypes of HPV,
including type 53, which is higher risk and becoming increasingly
prevalent. The specialized diagnostic kits can be found by
contacting the Company's sales representatives.
![(PRNewsfoto/Virax Biolabs) (PRNewsfoto/Virax Biolabs)](https://mma.prnewswire.com/media/1879039/Virax_Biolabs_Logo_Logo.jpg)
Virax's Chairman of the Board and Chief Executive Officer,
James Foster commented "we are
excited to expand our ViraxClear line of tests into an additional
significant area of concern. These tests will cover more genotypes,
have shorter processing times and lower costs than the currently
available HPV tests in Europe. As
we are able to supply around 200,000 of these tests per week, we
have a significant opportunity to capture some market share."
HPV is one of the most prevalent sexually transmitted infections
in the developed world. HPV is also the primary cause of cervical
cancer in women with around 33,000 cases and 15,000 deaths annually
in the EU, according to the European Centre for Disease Prevention
and Control. Globally, HPV is estimated to cause over 600,000 cases
of cervical cancer annually by the World Health Organization.
About Virax Biolabs Group
Limited
Founded in 2013, Virax Biolabs is an Innovative Biotechnology
company focused on the diagnosis of and the detection of immune
responses to viral diseases.
In addition to distributing an array of viral test kits in
unique geographies, Virax Biolabs Group Limited is currently
developing a proprietary T-Cell Test technology with the intention
of providing an immunology profiling platform that assesses each
individual's immune risk profile against major global viral
threats. T-Cell testing can be particularly effective in the
management and therapeutics of COVID-19 as well as other threats
including Monkeypox, Hepatitis B, Malaria, Herpes and Human
Papillomavirus. For more information, please visit
www.viraxbiolabs.com.
Safe Harbor Statement
This press release contains forward-looking statements. In
addition, from time to time, we or our representatives may make
forward-looking statements orally or in writing. We base these
forward-looking statements on our expectations and projections
about future events, which we derive from the information currently
available to us. Such forward-looking statements relate to future
events or our future performance, including: our financial
performance and projections; our growth in revenue and earnings;
and our business prospects and opportunities. You can identify
forward-looking statements by those that are not historical in
nature, particularly those that use terminology such as "may,"
"should," "expects," "anticipates," "contemplates," "estimates,"
"believes," "plans," "projected," "predicts," "potential," or
"hopes" or the negative of these or similar terms. In evaluating
these forward-looking statements, you should consider various
factors, including: our ability to change the direction of the
Company; our ability to keep pace with new technology and changing
market needs; and the competitive environment of our business.
These and other factors may cause our actual results to differ
materially from any forward-looking statement. Forward-looking
statements are only predictions. The forward-looking events
discussed in this press release and other statements made from time
to time by us or our representatives, may not occur, and actual
events and results may differ materially and are subject to risks,
uncertainties, and assumptions about us. We are not obligated to
publicly update or revise any forward-looking statement, whether as
a result of uncertainties and assumptions, the forward-looking
events discussed in this press release and other statements made
from time to time by us or our representatives might not occur.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/virax-biolabs-introduces-human-papillomavirus-hpv-test-kit-301713053.html
SOURCE Virax Biolabs